ALLOPURINOL

Post-LOE

allopurinol

Aurobindo Pharma

ANDAORALTABLET

Approved

Apr 2025

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

ALLOPURINOL (allopurinol) by Aurobindo Pharma is xanthine oxidase inhibitors [moa]. Approved for leukemia, lymphoma. First approved in 2025.

Drug data last refreshed 19h ago

Mechanism of Action

Xanthine Oxidase Inhibitors

Pharmacologic Class:

Xanthine Oxidase Inhibitor

Indications (2)

leukemia lymphoma

Clinical Trials (20)

NCT07089888Phase 3Recruiting

A Study of Dotinurad Versus Allopurinol in Tophaceous Gout

Started Aug 2025

250 enrolled

Tophaceous Gout

NCT07089875Phase 3Recruiting

A Study of Dotinurad Versus Allopurinol in Participants With Gout

Started Aug 2025

500 enrolled

Gout

NCT06056570Phase 1/2Completed

Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia

Started Oct 2023

20 enrolled

GoutHyperuricemia

NCT05665699Phase 2Active Not Recruiting

Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout

Started Apr 2023

80 enrolled

Gout

NCT05253833Phase 2Completed

Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout

Started Aug 2022

42 enrolled

GoutArthritis, GoutyHyperuricemia+1 more

Worked on ALLOPURINOL at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.